Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Distribution of predictive factors in relation to subgroups and in relation to treatment, with corresponding rates for pCR

From: Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast

  ddAT – Tamoxifen (n = 98) ddAT + Tamoxifen (n = 98)
  n % pCR (%) n % pCR (%)
Menopausal status:       
Premenopausal 50 51.0 10.0 56 57.1 12.5
Peri-/postmenopausal 48 49.0 8.3 42 42.9 2.4
Tumour size:       
≤ 4 cm 58 59.2 12.1 56 57.1 8.9
> 4 cm 40 40.8 5.0 42 42.9 7.1
Clinical nodal status:       
Negative 52 53.1 15.4 46 46.9 13.0
Positive 46 46.9 2.2 52 53.1 3.9
Grade:       
I/II 46 47.9 4.3 44 44.9 0
III 50 52.1 14.0 54 55.1 14.8
Clinical response after two cycles:       
cPR/cCR 45 48.9 13.3 50 54.3 12.0
cNC/cPD 47 51.1 4.3 42 45.7 4.8
ER:       
0 to 9% 40 40.8 17.5 46 46.9 17.4
10 to 100% 58 59.2 3.5 52 53.1 0
PgR:       
0 to 9% 55 56.1 14.5 64 65.3 12.5
10 to 100% 43 43.9 2.3 34 34.7 0
Ki-67:       
0 to 15% 42 42.9 2.4 33 33.7 6.1
16 to 30% 21 21.4 0 22 22.5 4.5
31 to 100% 35 35.7 22.9 43 43.9 11.6
HER2:       
0 to 2+ 73 76.0 9.6 75 76.5 10.7
3+ 23 24.0 8.7 23 23.5 0
p53:       
1 to 50% 47 48.0 6.4 44 44.9 4.5
0 + 51 to 100% 51 52.0 11.8 54 55.1 11.1
bcl-2:       
0 to 1+ 60 61.2 13.3 64 65.3 12.5
2 to 3+ 38 38.8 2.6 34 34.7 0
  1. cCR, clinical complete response; cNC, clinical no change; cPD, clinical progressive disease; cPR, clinical partial response; ddAT, dose-dense Adriblastin (Doxorubicin) and Taxotere (Docetaxel); ER, oestrogen receptor; HER2, human epidermal growth factor receptor 2; pCR, pathological complete remission; PgR, progesterone receptor.